The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
Open accessAbstract
Objective: B cells are likely to contribute to the pathogenesis of systemic lupus erythematosus (SLE), and rituximab induces depletion of B cells. The Exploratory Phase II/III SLE Evaluation of Rituximab (EXPLORER) trial tested the efficacy and safety of rituximab versus placebo in patients with moderately‐to‐severely active extrarenal SLE. Methods: Patients entered with ≥1 British Isles Lupus Assessment Group (BILAG) A score or ≥2 BILAG B scores despite background immunosuppressant therapy, which was continued during the trial. Prednisone was added and subsequently tapered. Patients were randomized at a ratio of 2:1 to receive rituximab (1,000 mg) or placebo on days 1, 15, 168, and 182. Results: In the intent‐to‐treat analysis of 257 patients, background treatment was evenly distributed among azathioprine, mycophenolate mofetil, and methotrexate. Fifty‐three percent of the patients had ≥1 BILAG A score at entry, and 57% of the patients were categorized as being steroid dependent. No differences were observed between placebo and rituximab in the primary and secondary efficacy end points, including the BILAG‐defined response, in terms of both area under the curve and landmark analyses. A beneficial effect of rituximab on the primary end point was observed in the African American and Hispanic subgroups. Safety and tolerability were similar in patients receiving placebo and those receiving rituximab. Conclusion: The EXPLORER trial enrolled patients with moderately‐to‐severely active SLE and used aggressive background treatment and sensitive cutoffs for nonresponse. No differences were noted between placebo and rituximab in the primary and secondary end points. Further evaluation of patient subsets, biomarkers, and exploratory outcome models may improve the design of future SLE clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
(2016) · Diagnostic Imaging: Brain · doi:10.1016/b978-0-323-37754-6.50094-4 · Cited by 3,990
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus
Arbuckle, M. R., McClain, M. T., Rubertone, M. V., Scofield, R. H., Dennis, G. J., James, J. A., & Harley, J. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021933 · Cited by 2,578
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Cohen, S. B., Emery, P., Greenwald, M. W., Dougados, M., Furie, R. A., Genovese, M. C., Keystone, E. C., Loveless, J. E., Burmester, G., Cravets, M. W., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22025 · Cited by 1,638
Rahman, A., & Isenberg, D. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmra071297 · Cited by 1,632
Self-citationRusso, J., Trujillo, C. A., Wingerson, D., Decker, K., Ries, R., Wetzler, H., & Roy-Byrne, P. (1998) · Medical Care · doi:10.1097/00005650-199805000-00015 · Cited by 1,308
Renal-Limited “Lupus-Like” Nephritis: How Much of a Lupus
Maziad, A. S. A., Torrealba, J., Seikaly, M. G., Hassler, J. R., & Hendricks, A. R. (2017) · Case Reports in Nephrology and Dialysis · doi:10.1159/000475493 · Cited by 1,299
Cited by
Tsokos, G. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1100359 · Cited by 2,736
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Fanouriakis, A., Kostopoulou, M., Alunno, A., Aringer, M., Bajema, I., Boletis, J. N., Cervera, R., Doria, A., Gordon, C., Govoni, M., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215089 · Cited by 2,011
Self-citationHahn, B. H., McMahon, M. A., Wilkinson, A., Wallace, W. D., Daikh, D. I., FitzGerald, J. D., Karpouzas, G. A., Merrill, J. T., Wallace, D. J., Yazdany, J., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21664 · Cited by 1,463
Self-citationRovin, B. H., Furie, R., Latinis, K., Looney, R. J., Fervenza, F. C., Sanchez‐Guerrero, J., Maciuca, R., Zhang, D., Garg, J. P., Brunetta, P., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34359 · Cited by 1,461
Self-citationKaul, A., Gordon, C., Crow, M. K., Touma, Z., Urowitz, M. B., van Vollenhoven, R., Ruiz-Irastorza, G., & Hughes, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.39 · Cited by 1,391
Self-citationKiriakidou, M., & Ching, C. L. (2020) · Annals of Internal Medicine · doi:10.7326/aitc202006020 · Cited by 821
Systemic lupus erythematosus: Diagnosis and clinical management
Fava, A., & Petri, M. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.11.001 · Cited by 754
Lisnevskaia, L., Murphy, G., & Isenberg, D. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60128-8 · Cited by 752
Self-citationPersonalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients
Banchereau, R., Hong, S., Cantarel, B., Baldwin, N., Baisch, J., Edens, M., Cepika, A.-M., Acs, P., Turner, J., Anguiano, E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.03.008 · Cited by 731
B cell depletion therapies in autoimmune disease: advances and mechanistic insights
Lee, D. S. W., Rojas, O. L., & Gommerman, J. L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00092-2 · Cited by 658
Management strategies and future directions for systemic lupus erythematosus in adults
Durcan, L., O'Dwyer, T., & Petri, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30237-5 · Cited by 648
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
Mougiakakos, D., Krönke, G., Völkl, S., Kretschmann, S., Aigner, M., Kharboutli, S., Böltz, S., Manger, B., Mackensen, A., & Schett, G. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2107725 · Cited by 610
Immunopathogenic mechanisms of systemic autoimmune disease
Wahren-Herlenius, M., & Dörner, T. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60954-x · Cited by 593
Bruce, I. N., O'Keeffe, A. G., Farewell, V., Hanly, J. G., Manzi, S., Su, L., Gladman, D. D., Bae, S.-C., Sanchez-Guerrero, J., Romero-Diaz, J., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-205171 · Cited by 567
Self-citationNovel paradigms in systemic lupus erythematosus
Dörner, T., & Furie, R. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30546-x · Cited by 565
The Pathogenesis of Lupus Nephritis
Lech, M., & Anders, H.-J. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013010026 · Cited by 496
Novel evidence‐based systemic lupus erythematosus responder index
Furie, R. A., Petri, M. A., Wallace, D. J., Ginzler, E. M., Merrill, J. T., Stohl, W., Chatham, W. W., Strand, V., Weinstein, A., Chevrier, M. R., et al. (2009) · Arthritis Care & Research · doi:10.1002/art.24698 · Cited by 490
Self-citationPathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective
Moulton, V. R., Suarez-Fueyo, A., Meidan, E., Li, H., Mizui, M., & Tsokos, G. C. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.05.006 · Cited by 469
Taming lupus-a new understanding of pathogenesis is leading to clinical advances
Liu, Z., & Davidson, A. (2012) · Nature Medicine · doi:10.1038/nm.2752 · Cited by 433
CAR T-cell therapy in autoimmune diseases
Schett, G., Mackensen, A., & Mougiakakos, D. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01126-1 · Cited by 430
Terrier, B., Amoura, Z., Ravaud, P., Hachulla, E., Jouenne, R., Combe, B., Bonnet, C., Cacoub, P., Cantagrel, A., De Bandt, M., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27541 · Cited by 411
Hoi, A., Igel, T., Mok, C. C., & Arnaud, L. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00398-2 · Cited by 399
Kansal, R., Richardson, N., Neeli, I., Khawaja, S., Chamberlain, D., Ghani, M., Ghani, Q.-U.-A., Balazs, L., Beranova-Giorgianni, S., Giorgianni, F., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav1648 · Cited by 382
Murine Models of Systemic Lupus Erythematosus
Perry, D., Sang, A., Yin, Y., Zheng, Y.-Y., & Morel, L. (2011) · BioMed Research International · doi:10.1155/2011/271694 · Cited by 378
Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy
Pierpont, T. M., Limper, C. B., & Richards, K. L. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00163 · Cited by 374
Gordon, C., Amissah-Arthur, M.-B., Gayed, M., Brown, S., Bruce, I. N., D’Cruz, D., Empson, B., Griffiths, B., Jayne, D., Khamashta, M., et al. (2018) · Rheumatology · doi:10.1093/rheumatology/kex286 · Cited by 365
Self-citationThe pathogenesis of systemic lupus erythematosus—an update
Choi, J., Kim, S. T., & Craft, J. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.10.004 · Cited by 360
Systemic Lupus Erythematosus in Children and Adolescents
Levy, D. M., & Kamphuis, S. (2012) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2012.03.007 · Cited by 359
Redefining lupus nephritis: clinical implications of pathophysiologic subtypes
Yu, F., Haas, M., Glassock, R., & Zhao, M.-H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.85 · Cited by 340
Wallace, D. J., Kalunian, K., Petri, M. A., Strand, V., Houssiau, F. A., Pike, M., Kilgallen, B., Bongardt, S., Barry, A., Kelley, L., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202760 · Cited by 337
Self-citationKiriakidou, M. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-7-201310010-01004 · Cited by 333
Wang, D., Li, J., Zhang, Y., Zhang, M., Chen, J., Li, X., Hu, X., Jiang, S., Shi, S., & Sun, L. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4520 · Cited by 315
Glucocorticoids—All-Rounders Tackling the Versatile Players of the Immune System
Strehl, C., Ehlers, L., Gaber, T., & Buttgereit, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01744 · Cited by 308
Isenberg, D., Gordon, C., Licu, D., Copt, S., Rossi, C. P., Wofsy, D., Babini, A., Lazaro, M., Lucero, E., Merono, C., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-205067 · Cited by 306
Self-citationThe role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus
Cancro, M. P., D’Cruz, D. P., & Khamashta, M. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38010 · Cited by 283
Mechanisms of B cell autoimmunity in SLE
Dörner, T., Giesecke, C., & Lipsky, P. E. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3433 · Cited by 283
Wang, D., Zhang, H., Liang, J., Li, X., Feng, X., Wang, H., Hua, B., Liu, B., Lu, L., Gilkeson, G. S., et al. (2013) · Cell Transplantation · doi:10.3727/096368911x582769c · Cited by 268
Morand, E., Pike, M., Merrill, J. T., van Vollenhoven, R., Werth, V. P., Hobar, C., Delev, N., Shah, V., Sharkey, B., Wegman, T., et al. (2023) · Arthritis & Rheumatology · doi:10.1002/art.42391 · Cited by 266
Self-citationB cells as therapeutic targets in SLE
Sanz, I., & Lee, F. E.-H. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.68 · Cited by 261
Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders
Kaegi, C., Wuest, B., Schreiner, J., Steiner, U. C., Vultaggio, A., Matucci, A., Crowley, C., & Boyman, O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01990 · Cited by 260
Berman, H., Rodríguez-Pintó, I., Cervera, R., Morel, N., Costedoat-Chalumeau, N., Erkan, D., Shoenfeld, Y., & Espinosa, G. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.05.004 · Cited by 259
Lewis, M. J., & Jawad, A. S. (2016) · Rheumatology · doi:10.1093/rheumatology/kew399 · Cited by 259
Approaches for estimating minimal clinically important differences in systemic lupus erythematosus
Rai, S. K., Yazdany, J., Fortin, P. R., & Aviña-Zubieta, J. A. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0658-6 · Cited by 251
Clowse, M. E. B., Wallace, D. J., Furie, R. A., Petri, M. A., Pike, M. C., Leszczyński, P., Neuwelt, C. M., Hobbs, K., Keiserman, M., Duca, L., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.39856 · Cited by 235
Self-citationPeripheral blood B cell depletion after rituximab and complete response in lupus nephritis
Gomez Mendez, L. M., Cascino, M. D., Garg, J., Katsumoto, T. R., Brakeman, P., Dall’Era, M., Looney, R. J., Rovin, B., Dragone, L., & Brunetta, P. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01070118 · Cited by 188
Self-citationImmunomodulators in SLE: Clinical evidence and immunologic actions
Durcan, L., & Petri, M. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.06.010 · Cited by 92
Immune cell dysregulation as a mediator of fibrosis in systemic sclerosis
Fang, D., Chen, B., Lescoat, A., Khanna, D., & Mu, R. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00864-7 · Cited by 84
Pego‐Reigosa, J. M., Cobo‐Ibáñez, T., Calvo‐Alén, J., Loza‐Santamaría, E., Rahman, A., Muñoz‐Fernández, S., & Rúa‐Figueroa, Í. (2013) · Arthritis Care & Research · doi:10.1002/acr.22035 · Cited by 74
Metadata
- Authors
- Merrill, J. T., Neuwelt, C. M., Wallace, D. J., Shanahan, J. C., Latinis, K. M., Oates, J. C., Utset, T. O., Gordon, C., Isenberg, D. A., Hsieh, H., Zhang, D., & Brunetta, P. G.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2009-12-28
- Volume
- 62
- Issue
- 1
- Pages
- 222-233
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2046330020
- Cited by
- 1,409
- References
- 46
- FWCI
- 50.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.